Targeted enhanced surveillance to observe vaccine impact against Pneumococcus

Not Applicable

Recruiting

• Conditions: Pneumonia; Streptococcus pneumoniae; Empyema; Infection - Studies of infection and infectious agents; Respiratory - Other respiratory disorders / diseases; Public Health - Other public health

• Registration Number: ACTRN12614000354684
• Lead Sponsor: niversity of New South Wales

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-04-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 2200

Inclusion Criteria

1. Children < 18 years old hospitalized <24 hours
2. Xray confirmed pneumonia
3. Presumed infective aetiology
4. A full blood count performed and at least 250microL of blood in an EDTA tube available for further testing.

Exclusion Criteria

1. Significant co-morbidity, including haematologic malignancy, post stem cell or solid organ transplantation, cystic fibrosis, congenital malformation of the lung
2. Hospitalised within 14 days of presentation

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine the real-world effectiveness of pneumococcal conjugate vaccine for preventing hospitalisation for Streptococcus pneumoniae (SP) confirmed and all-cause pneumonia; by testing patient blood, nasopharyngeal and pleural fluid samples to identify SP and perform further molecular testing to determine the isolates specific serotype. To determine vaccine effectiveness, idetified serotypes will be compared to those present in the current 13vPCV.[At completion of the observational study (36 months)]